From the Editor

Dec 01, 2001
Pharmaceutical Executive
No one can pinpoint the precise instant it happened, but the dull cloud of our universe suddenly cleared. About a half-billion years had gone by since the Big Bang, finally giving the condensing proto-stars and quasars enough time to sweep a veil of dust from the young cosmos. Their light then penetrated the darkness and, along with that of countless other spawning suns, has traveled the skies ever since.
Oct 01, 2001
Pharmaceutical Executive
I heard the first bird of the morning whistling to his lover. Their small wings owned the sky again while the people fled for cover.
Sep 01, 2001
Pharmaceutical Executive
In religion, belief comes first. In science, it comes last. And in politics, as in publishing, you can often find it for sale.
Aug 01, 2001
Pharmaceutical Executive
That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?
Jul 01, 2001
Pharmaceutical Executive
Is the pharmaceutical industry surrounded by its critics? Can the industry be liberated from the moral bind others want to impose on it? Those are questions I asked and attempted to answer in two recent editorials (PE April and June 2001). Actually, the simple answer was yes to both. But other answers prove more complex.
Jun 01, 2001
Pharmaceutical Executive
I intended to write an entirely different column this month. Something like, What the Bush administration has done for you-the pharmaceutical industry-lately. Such as making it harder to do stem-cell research and pursuing an investigation into antigeneric activities. But something else happened. My father died. Now I have no room left in my mind or heart for other matters.
May 01, 2001
Pharmaceutical Executive
Pharmaceutical executives should study their own scientists. They construct clever tools to explore convoluted phenomena. They are the true friends of complexity.
Apr 01, 2001
Pharmaceutical Executive
Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.
Mar 01, 2001
Pharmaceutical Executive
}Drug costs continue to rise at an alarming rate. Two major reasons for the increasing costs are introductions of new drugs and direct-to-consumer advertising campaigns that have been effective in marketing expensive name brand drugs.}
Feb 01, 2001
Pharmaceutical Executive
Managing expectations is the new alchemy. All manipulators of opinion, from the US president down to the humblest peddler, now seek to minimize what people expect
native1_300x100
lorem ipsum